Core Insights - ONWARD Medical N.V. announces changes to its Board of Directors, highlighting the appointment of Professor Tim Denison and the departure of Professor Gregoire Courtine [2][5][7] Company Overview - ONWARD Medical is a leading neurotechnology company focused on developing therapies to restore movement and function in individuals with spinal cord injuries (SCI) and other movement disabilities [10][11] - The company has developed ARC Therapy, which has received 10 Breakthrough Device Designations from the US FDA, and its ARC-EX System is cleared for commercial sale in the US [10] Board Changes - Professor Tim Denison has been appointed to the Board, taking over the seat previously held by Professor Gregoire Courtine, who will continue as Co-Founder and Science Advisor [3][5][8] - Denison brings extensive experience in neurotechnology, having previously served as Vice President of Research & Core Technology at Medtronic and is a co-founder of Amber Therapeutics [4][8] Research and Development Focus - The Neuro-X Institute, directed by Courtine, is a multidisciplinary research hub aimed at accelerating therapies for neurological disorders, while NeuroRestore focuses on recovery therapies for SCI, Parkinson's disease, and stroke [6][10] - ONWARD Medical's commitment to innovation is underscored by its ongoing development of investigational products, including the ARC-IM system [10][18]

Besides celebrating shared bonds, culture and history, the leaders of Britain and France will face the hard grind of, among other things, enhancing Europe’s security—and paying for it https://t.co/PN9T3OgsmZ ...

Your biggest concern at the moment seems to be the appreciation of the euro against the dollar. We were in Sintra earlier this week where the vice president, Mr. . de Guindos, was talking about 120 as the limit.What is your take on this. So I won't comment on my colleagues commands. It's a general rule, but we look closely at the volatility of the exchange rate.It has been significant since the start of the year with a 13% appreciation of the euro against the dollar. By the way, it's not a specific apprecia ...

He says that thimerosal is a neurotoxin that causes neurodevelopmental disorders, notably autism, in children. An American ban on it now seems imminent. The evidence, however, strongly suggests this is a mistake https://t.co/2qQlqCU4a9 ...

The euro cannot quickly supplant the dollar as the anchor of the world’s financial system, European Central Bank Governing Council member Gabriel Makhlouf said https://t.co/vjuI3Uu2WX ...

Danes hug Europe tight as geopolitical challenges loom for the EU https://t.co/vPJLkuPj2u ...

This Affordable European Country Is Launching A Digital Nomad Visa: Here’s What You Need To Know https://t.co/pZ59e2Ikkm ...

The ECB risks undershooting its inflation target if the euro’s strength persists, says Bank of France Governor Francois Villeroy de Galhau https://t.co/okqNfs4SvI https://t.co/CbYvIpQYKp ...

Deutsche Bank says the Spanish economy will keep outpacing the euro area’s growth after inflation and borrowing costs eased https://t.co/yPWiFtO3ps ...

Core Insights - Nxera Pharma will receive US$4.8 million in milestone payments from Centessa Pharmaceuticals due to the initiation of clinical development of ORX142, a novel orexin receptor 2 (OX2R) agonist [1][2] - The milestone payments include US$1.8 million recognized as revenue in Q2 2025 and US$3.0 million in Q3 2025 [2] Company Overview - Nxera Pharma is a technology-driven biopharma company focused on developing specialty medicines for unmet medical needs in Japan and globally [3] - The company has established a commercial business in Japan to develop and market innovative medicines, addressing a growing market in the APAC region [3] Pipeline and Development - Nxera Pharma has an extensive pipeline of over 30 active programs, utilizing its NxWave™ discovery platform, targeting major unmet needs in neurology, metabolic diseases, and immunology [4] - The pipeline includes potentially first- and best-in-class candidates, advancing from discovery to late clinical stages in collaboration with leading pharmaceutical and biotech companies [4] Workforce and Locations - Nxera employs approximately 400 people across key locations including Tokyo, Osaka, London, Cambridge, Basel, and Seoul [5]